Kornimate/medical-research-clean huggingface dataset:
blood flow restriction study

Conditions: Ulnar Wrist Pain

Summary: the purpose of this study is to determine the strength, pain and functional benefits of early, low-load resistance training with blood flow restriction (bfr) in ulnar-sided wrist pain treated nonoperatively with immobilization for 4-6 weeks. we hypothesize that patients in the bfr group with have improved grip strength and patient reported outcome measure scores compared to the control group.

patients presenting to the hand therapy or hand surgery clinic who meet inclusion criteria will be screened, consented, and enrolled. this will include administration of the blood flow restriction screening questionnaire (appendix a). patients with non operatively managed ulnar-sided wrist pain, who have been immobilized for at least 4 weeks 0 days, but no more than 6 weeks 6 days, and are referred to stanford's hand therapy clinic, will receive either standard care or a standard care home program with low-load strengthening under a blood flow restricted (bfr) condition during their therapy sessions (appendix b). patients will be assigned to groups in simultaneous enrollment in two arms. the control group will receive standard rehabilitation during therapy visits plus a home program that will be dictated based on the associated phase of rehabilitation 8 (appendix c). the treatment group will receive standard rehabilitation as a home program plus low-load resistance training with bfr application while at the hand therapy clinic for their appointments, both of which will be dictated based on the associated phase of rehabilitation (appendix d). therapists will use the omni-resistance exercise scale for rate of perceived exertion active muscles (omni-res rpe-am) (appendix e) to grade all strengthening exercises for each individual in both groups. the target rpe-am for each exercise will be 7-9 by the last set for resistance exercises in both control and treatment groups.

Eligibility criteria:
inclusion criteria: * all patients (\>18 years) undergoing outpatient rehabilitation at stanford hand therapy * english fluency and literacy * able to take informed consent * have acute or chronic ulnar-sided wrist pain referred for a course of hand therapy by a physician or advanced practice provider (app) and were treated with continuous immobilization for 4-6 weeks. * score of 3 or less on blood flow restriction screening questionnaire exclusion criteria: * concomitant injuries such as upper extremity fractures or other ligamentous injuries * tfcc surgery in the affected wrist * non-compliance with immobilization * patients who complete hand therapy at an outside facility * score of 4 or more on blood flow restriction screening questionnaire

Keywords: blood flow restriction
effect of alcohol consumption on the success rates

Conditions: Pulpitis - Irreversible

Summary: this prospective, randomized, double-blind clinical trial will be carried out conservative dentistry, faculty of dentistry, jamia millia islamia. seventy adult patients (35 alcoholic and 35 non-alcoholics) with symptomatic irreversible pulpits in a mandibular first or second molar will receive an ianb with 2% lidocaine. in case of pain during treatment, the procedure will be stopped, and the patients will be asked to rate the pain on the heft-parker scale. the injection shall be considered as successful if the patient reports pain scores less than 55 on the hp scale.


Eligibility criteria:
inclusion criteria: * symptomatic carious exposed mandibular first or second molars. * alcoholic patients: patient with low-moderate drinking levels according to the us national institute on alcohol abuse and alcoholism * control patients: no history of alcohol consumption * positive and prolonged response to thermal sensitivity tests and electric pulp test. * vital coronal pulp on access cavity preparation. * american society of anesthesiologists class i or ii medical history. * ability to understand the use of pain scales. exclusion criteria: * active pain in more than 1 teeth * teeth with fused roots. * radiographic evidence of an extra root. * large restorations with overhanging margins. * full crowns or deep periodontal pockets. * hypertension or cardiovascular diseases, compromised immunity, active infection or inflammation * known allergy or contraindications to any content of the local anesthetic solution or non-steroidal anti-inflammatory drugs (nsaids) * history of known or suspected drug abuse. * taking any drugs which could affect the pain perception, e.g, opioids, antidepressants, anticonvulsants, muscle relaxants, anxiolytics, sedatives, nsaids. 23 * pregnant or breastfeeding patients. * patients with asthma, gastric ulcers, bleeding disorders.
study of evobrutinib in participants with rms

Conditions: Relapsing-remitting Multiple Sclerosis

Summary: the study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus interferon-beta-1a (avonex®), once a week intramuscularly in participants with relapsing multiple sclerosis (rms).


Eligibility criteria:
inclusion criteria: * participants diagnosed with rms (relapsing-remitting multiple sclerosis \[rrms\] or secondary progressive multiple sclerosis \[spms\] with relapses) in accordance with 2017 revised mcdonald criteria (thompson 2018). * participants with one or more documented relapses within the 2 years before screening with either: a. one relapse which occurred within the last year prior to randomization, or b. the presence of at least 1 gadolinium-enhancing (gd+) t1 lesion within 6 months prior to randomization. * participants have edss score of 0 to 5.5 at baseline. participants with an edss score \<= 2 at screening are only eligible for participation if their disease duration (time since onset of symptoms) is no more than 10 years. * participants are neurologically stable for \>= 30 days prior to both screening and baseline. * female participants must be neither pregnant nor breast-feeding and must lack child-bearing potential, as defined by either: post-menopausal or surgically sterile or use an effective method of contraception for the duration of the study. * participants have given written informed consent prior to any study-related procedure. * other protocol defined inclusion criteria could apply exclusion criteria: * participants diagnosed with progressive ms, in accordance with the 2017 revised mcdonald criteria as follows: a). participants with primary progressive ms. b). participants with secondary progressive ms without evidence of relapse. * disease duration more than (\>) 10 years in participants with an edss =\< 2.0 at screening. * immunologic disorder other than ms, or any other condition requiring oral, intravenous (iv) , intramuscular, or intra-articular corticosteroid therapy, with the exception of well-controlled type 2 diabetes mellitus or well controlled thyroid disease. * other protocol defined exclusion criteria could apply.

Keywords: evobrutinib avonex® interferon-beta 1a relapsing multiple sclerosis
impact on quality of life by moxibustion in chemotherapy for cancer

Conditions: Cancer

Summary: most cancer patients experience multiple symptoms related to chemotherapy and use cam (complementary and alternative medicine) as an adjunct to conventional treatment. moxibustion is traditional korean medical therapeutic method and uses the heat generated by burning herbal preparations containing artemisia vulgaris to stimulated acupoint. herein, the investigators propose an open-label pilot study investigating the effectiveness of moxibustion stimulation at abdominal acupoint on quality of life in cancer patients under chemotherapy.


Eligibility criteria:
inclusion criteria: * diagnostic histopathology of cancer * performance status of 0-2 on the european cooperative oncology group (ecog) performance scale. * patients on chemotherapy currently have plan to receive chemotherapy for more than 6 weeks. * follow-up possible during the clinical trial * informed signed consent exclusion criteria: * patients with severe heart disease and hypertension that is not controlled (systolic blood pressure \>160 or diastolic blood pressure \>100) * patients with diabetes that is not controlled (fbst \>180 or bst\>250) * patients with abdominal injury or severe ascites can't be received moxibustion therapy on abdomen. * hypersensitive section to moxibustion treatment * inability to comprehend or express oneself in the korean language * an individual deemed to be ineligible by a physician * refusal to participate in this trial or to provide informed consent.
genetics of reproductive disorders (including kallmann syndrome) and cleft lip and/or palate

Conditions: Kallmann Syndrome; Hypogonadotropic Hypogonadism; Hypothalamic Amenorrhea; Polycystic Ovarian Syndrome; Precocious Puberty; Cleft Lip and Palate; Cleft Palate; Cleft Lip

Summary: the purpose of this study is to explore the genetic basis of reproductive disorders and cleft lip and/or palate.

the world health organization estimates approximately 10% of couples experience some sort of infertility problem. in humans, puberty is the process through which we develop reproductive capacity. the timing of puberty varies greatly in the general population and is influenced by both genetic and environmental factors. in extreme cases of pubertal delay, puberty progresses only partially or not at all and results in the clinical picture of congenital hypogonadotropic hypogonadism (chh), either accompanied by anosmia in 50% of cases (kallmann syndrome \[ks\]) or by normal sense of smell (nchh), with a male: female ratio of 4:1. chh is due to gnrh deficiency (incidence 1: 4,000-10,000) and result in the failure of sexual maturation and infertility. it is genetically heterogeneous, with multiple patterns of inheritance and several associated loci. in the clinical spectrum of gnrh deficiency, chh may also be associated with a cleft lip/palate (cl/p) in 5 to 7% of cases. however, this prevalence increases up to 40% in chh patients carrying a mutation in a cl/p gene, suggesting a genetic overlap between chh and cl/p. disorders of puberty have provided insight into the biology of reproduction and genetic technologies have enabled us to deepen understanding in this field. the focus of this study is to better understand the genetic control of puberty and human reproduction as well as its link with cl/p. increasing understanding of the molecular basis (genes) of inherited reproductive disorders and cl/p may enable investigators to: * improve diagnostic testing and treatments for these problems * develop new diagnostic tests and therapies for patients * enhance counseling for patients and families with reproductive disorders * enhance counseling for patients and families with cleft lip/palate

Eligibility criteria:
inclusion criteria:(any of the following conditions) * hypogonadotropic hypogonadism * kallmann syndrome * adult-onset hypogonadotropic hypogonadism * hypothalamic amenorrhea * polycystic ovarian syndrome * primary gonadal failure * precocious puberty * cleft lip/palate * family members of the above groups exclusion criteria: * acute illness/hospitalization * pituitary tumors * iron overload (hemochromatosis) * infiltrative diseases (sarcoidosis) * chronic alcohol abuse * illicit drug use * anabolic steroid abuse

Keywords: gnrh deficiency hypogonadism anosmia infertility cleft lip cleft palate cryptorchidism microphallus
a study to evaluate the effect of oral paliperidone extended-release and oral risperidone immediate-release on cognitive function in clinically stable patients with schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to compare the effect of oral paliperidone extended-release and oral risperidone immediate-release on cognitive function, especially the category fluency of cognitive abilities screening instrument, chinese version (casi c-2.0), in patients with an established diagnosis of schizophrenia.

this is a 28-week, randomized (the study medication is assigned by chance), open-label (all people know the identity of the intervention), active-controlled (patients are assigned to either a recognized effective treatment or the study medication) comparative study. all patients will enter a run-in period to receive a stable therapeutic dose of oral risperidone immediate-release for at least 4 weeks. after the 4-week run-in period, patients will be randomly assigned to either remain on oral risperidone immediate-release (ir) or to receive a therapeutic dose of oral paliperidone extended-release (er) and patients will be prospectively followed for a 24-week treatment phase. the treatment phase is composed of a 4-week flexible dose period followed by a 20-week stable dose period. during the 4-week flexible dose period, the dose of paliperidone er or risperidone ir may be increased or decreased for each patient if clinically indicated (eg, significant side effects emerge or there is evidence of a lack of efficacy). at the end of 4-week flexible dose period, the final dose should be maintained for the 20-week fixed-dose period. efficacy and safety will be assessed at baseline (week 0) and weeks 4, 12, and 24.

Eligibility criteria:
inclusion criteria: * diagnosed with schizophrenia * cognitive abilities screening instrument c-2.0 total score between 50 and 85 (inclusive) at baseline * baseline positive and negative syndrome scale score between 60 and 85 (inclusive) * clinical global impression-severity change less than or equal to 1 in the month prior to randomization * patients on a stable therapeutic dose of oral risperidone ir (between 3-6 mg/day) for at least 4 weeks prior to randomization exclusion criteria: * treatment refractory patients, defined as failure of more than or equal to 2 adequate trials of second generation antipsychotic treatment for schizophrenia * history of neuroleptic malignant syndrome * allergy or hypersensitivity to risperidone or paliperidone, or to any of the excipients of oral risperidone ir or paliperidone er tablets * participants who have taken paliperidone er in the past * participants who have been treated with clozapine or any long-acting injectable (depot) antipsychotic within 3 months before randomization

Keywords: schizophrenia paliperidone risperidone paliperidone extended-release (er) risperidone immediate-release (ir)
neural and hormonal influences on sex differences in risk for aud

Conditions: Alcohol Use Disorder

Summary: the sex gap in alcohol consumption is closing rapidly, due to alarming increases among women. from 2002-2013, alcohol use disorder (aud) increased 84% for women, compared to 35% for men. as such, there is an urgent need to determine the factors underlying sex differences in risk for aud. current addiction models propose three domains that drive problematic alcohol use and serve as candidate sex-specific risk factors: executive function, negative emotionality, and incentive salience. data suggest that poor inhibitory control, a key component of executive function, is a stronger risk factor for women than for men. moreover, there is have preliminary evidence that female drinkers show less engagement of neural inhibitory circuitry, and that this sex difference is influenced by estradiol. however, the degree to which hormonally-moderated sex differences in executive function extend to the negative emotionality and incentive salience domains, and how these sex differences influence current and future drinking is unknown. the goal of this study is to identify the mechanisms underlying sex-specific risk for aud, and ultimately to help develop sex-specific prevention and treatment efforts. the overall objective of this trial is to determine the neural and hormonal factors contributing to sex-specific risk for aud in three addiction domains: inhibitory control (executive function), negative emotionality, and alcohol cue reactivity (incentive salience).


Eligibility criteria:
inclusion criteria: * consume 4/5 drinks per week * fluent in english * high school education * right-handed * regular menstrual cycles (women) exclusion criteria: * serious medical problems * body weight \ 210 lbs * current medical or psychiatric conditions requiring medication for which alcohol is contraindicated * substance use disorder other than alcohol * current or recent history of inpatient/intensive treatment for addictive behaviors * pregnant, nursing, on hormonal contraception * contraindications for fmri * smoking \> 5 cigarettes per day

Keywords: sex inhibitory control risk factor hormone fmri menstrual cycle
transitioning open heart surgery patients from insulin infusions to detemir

Conditions: Diabetes Mellitus

Summary: in this study we will determine the proper method for transitioning patients from a continuous insulin infusion to periodic injections of a newer long-acting insulin called detemir (levemir).

high sugar (glucose) is common after surgery, even in patients who do not have diabetes. high glucose contributes to severe hospital complications and even death. insulin infusions appear to reduce this risk, but are generally only continued for a few days after surgery. in this study, we will determine the proper method for transitioning patients from a continuous insulin infusion to periodic injections of a newer long-acting insulin called detemir (levemir). 90 patients who have undergone recent open heart surgery and are requiring an insulin infusion will be enrolled. they will be randomly assigned to one of three doses of detemir, which consists of 50%, 65%, or 80% of the total daily insulin infusion requirement in the fasting state. subjects will also receive identical mealtime coverage according to the amount of carbohydrate (glucose) that is ingested. it is expected that the high dose group will achieve superior glycemic control without excessive hypoglycemia.

Eligibility criteria:
inclusion criteria: * diabetes mellitus * post-cardiothoracic surgery * requiring an insulin infusion of at least 1 unit/hour * age 18-75 exclusion criteria: * glucocorticoids * total parenteral nutrition (tpn) or tube feeds * pregnancy * surgical procedures in the next 48 hours for whom intravenous (iv) insulin will be expected * expected length of stay less than 48 hours following cessation of the insulin drip * patients using subcutaneous insulin pumps * diabetic ketoacidosis * end-stage renal disease * end-stage liver disease * coma * potentially sensitive admissions: prisoners, human immunodeficiency virus(hiv), suicidality * unable to give consent in english

Keywords: diabetes hyperglycemia open heart surgery cardiothoracic surgery detemir insulin infusion intravenous insulin
comparative results of six biomaterials used in two-stage maxillary sinus

Conditions: Atrophy; Jaw, Edentulous, Partially; Sinus Floor Augmentation; Bone Substitutes; Bone Regeneration

Summary: objectives: the aim of the study was to compare histological and histomorphometric results of six bone substitute materials used as graft in two-stage maxillary sinus augmentation model, after 6-month-healing.

materials and methods: a two-stage sinus augmentation was carried out in six patients using mineralized solvent-dehydrated bone allograft (mcba), freeze-dried mineralized bone allograft (fdba), anor-ganic bovine bone (abb), equine-derived bone (eb); synthetic micromacroporous biphasic calcium-phosphate block consisting of 70% beta-tricalcium phosphate and 30% hydroxyap-atite (ha-β-tcp 30/70), or bioapatite-collagen (bc).

Eligibility criteria:
inclusion criteria: patients healthy, absence of systemic pathologies (asa class i), non-smokers, good oral hygiene, not pregnant or lactating, absence of painful symptoms and associated inflammatory or osteolytic pathologies, maxillary partial edentulism involving the premolar/molar areas, residual bone height between the sinus floor and alveolar ridge ranging from 2 to 4 mm, as measured on computerized tomography (ct) scan. - exclusion criteria: -

Keywords: sinus floor augmentation bone regeneration histology biocompatible materials bone transplantation
phase ii trial of allovectin-7® for head and neck cancer

Conditions: Head and Neck Cancer; Squamous Cell Carcinoma of the Oral Cavity or Oropharynx; Head and Neck Neoplasms; Carcinoma of the Head and Neck

Summary: the purpose of this clinical trial is to determine if allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. the trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression.

treatment - if you take part in this trial you will be treated for about four weeks. you will receive an injection of allovectin-7® by needle, directly into your tumor. this will be repeated 14 days later. the injections may be given in a doctor's office. a week later, you will undergo surgery to remove the tumor. your tumor will be measured before allovectin-7® treatment and before surgery to see if allovectin-7® was effective in shrinking it. this will be done by general physical exams and scans (such as x-ray scans). there will also be tests on the removed tumor to see if allovectin-7® helped to boost the immune system to attack the cancer.

Eligibility criteria:
in order to be in this trial, you must meet the enrollment criteria. below is a list of some of the enrollment criteria. * you have been diagnosed with head and neck cancer (also called squamous cell carcinoma of the mouth) * you have stage i or stage ii disease (a single mouth tumor which has not spread to other areas of the body) * surgery to remove your tumor is recommended * you have not received any prior therapy for head and neck cancer (e.g. radiation or chemotherapy) * you are able to carry out your normal daily activities

Keywords: cancer carcinoma neoplasm head cancer neck cancer tongue cancer lip cancer oral cavity oropharynx pharynx larynx squamous cell salivary glands tumor lesion cancer treatment clinical trial allovectin-7® otorhinolaryngologic neoplasm otolaryngologic cancer gene therapy immunotherapy cancer research cancer vaccine cancer cells
peripheral sensory input in central post stroke pain (cpsp)

Conditions: Central Post Stroke Pain

Summary: prospective, open-label study in 10 patients with central post stroke pain (cpsp). the study will evaluate the effects of peripheral nerve blockade on spontaneous pain and evoked thermal and mechanical responses in cpsp, and assesses the associated local anesthetic pharmacokinetics.


Eligibility criteria:
each subject must meet all of the following criteria: * age ≥18; * cpsp affecting an upper or a lower limb, in a distribution that may be completely covered by a peripheral nerve block; * patient fulfills all mandatory criteria for cpsp, fulfills at least one supportive criteria, and has definite cpsp by probability grading. * pain duration at least 3 months; * spontaneous pain intensity (average pain in past week) of ≥ 4 on 0-10 numerical rating scale (nrs). exclusion criteria subjects will not be enrolled if any of the following criteria exist: * not giving consent to participate in the study; * significant psychiatric or cognitive impairment; * moderate to severe renal or liver failure; * concomitant treatment with warfarin or other anticoagulants; * pregnancy or lactation.

Keywords: central post stroke pain nerve block